Table 1.
Baseline characteristics in PsA patients with or without enthesitis at baseline
| Characteristic | All patients | Patients with enthesitis (LEI EC ≥1) | Patients without enthesitis (LEI EC = 0) |
|---|---|---|---|
| Pooled randomized, treated patients, n | 1120a | 728b | 390c |
| Age, mean (s.d.), years | 46.6 (11.7) | 46.4 (11.4) | 47.0 (12.1) |
| Sex, % | |||
| Male | 52.1 | 49.9 | 56.4 |
| Female | 47.9 | 50.1 | 43.6 |
| Weight, mean (s.d.), kg | 84.9 (19.3) | 85.1 (20.1) | 84.5 (17.7) |
| BMI, mean (s.d.), kg/m2 | 29.2 (6.1) | 29.4 (6.4) | 28.8 (5.5) |
| Normal (<25), % | 25.5 | 25.8 | 25.1 |
| Overweight (≥25 and <30), % | 34.5 | 32.4 | 38.2 |
| Obese (≥30), % | 40.0 | 41.8 | 36.7 |
| PsA disease duration, mean (s.d.), years | 5.9 (6.1) | 6.1 (6.4) | 5.6 (5.4) |
| Joint counts, mean (s.d.) | |||
| Swollen (0–66) | 11.4 (7.4) | 12.3 (7.9) | 9.8 (6.0) |
| Tender (0–68) | 20.6 (13.3) | 23.8 (14.2) | 14.6 (8.6) |
| DAS28-CRP, mean (s.d.) | 5.1 (1.0) | 5.3 (1.0) | 4.7 (1.0) |
| Dactylitis at baselinec, % | 42.3 | 48.5 | 30.8 |
| Dactylitis severity score (1–60)c, mean (s.d.) | 8.2 (9.6) | 9.1 (10.3) | 5.6 (6.4) |
| Enthesitis (LEI) score (1–6), mean (s.d.) | 2.8 (1.6) d | 2.8 (1.6)e | — |
| HAQ-DI (0–3), mean (s.d.) | 1.2 (0.6)f | 1.3 (0.6) | 1.1 (0.6) |
| CRP, mean (s.d.), mg/dl | 1.8 (2.3) | 2.0 (2.5) | 1.5 (1.8) |
| IGA score (0–4), % | |||
| Cleared (0) | 2.4 | 2.9 | 1.5 |
| Minimal (1) | 16.5 | 15.2 | 19.0 |
| Mild (2) | 36.2 | 35.0 | 38.5 |
| Moderate (3) | 36.5 | 37.0 | 35.4 |
| Severe (4) | 8.4 | 9.9 | 5.6 |
| PASI score (0–72), mean (s.d.) | 9.5 (10.6) | 10.2 (11.3) | 8.1 (9.1) |
| <12, % | 74.4 | 72.4 | 78.2 |
| ≥12 and <20, % | 12.9 | 13.6 | 11.5 |
| ≥20, % | 12.7 | 14.0 | 10.3 |
| csDMARD use at baseline, % | 67.8 | 68.7 | 66.2 |
| MTX | 58.4 | 59.1 | 57.2 |
| Other | 9.4 | 9.6 | 9.0 |
Results are pooled across DISCOVER-1 and DISCOVER-2.
Among 1120 patients, 1118 were included in enthesitis analyses, eight of whom had enthesitis noted among the 4/6 LEI sites assessed at baseline (LEI EC ≥1, but actual LEI score incomplete and considered missing), and two with no enthesitis noted among the 4/6 LEI sites assessed at baseline were excluded from enthesitis analyses.
Includes eight patients with LEI EC ≥1 at baseline based on only 4/6 LEI sites evaluated.
Excludes two patients with no enthesitis noted at 4/6 LEI sites or no dactylitis noted at DSS sites assessed at baseline.
Among 1110 patients with non-missing/complete LEI scores at baseline.
Among 720 patients with non-missing/complete LEI scores at baseline.
n = 1119.
csDMARD: conventional synthetic DMARD; DSS: Dactylitis Severity Score; EC: enthesitis count; IGA: Investigator’s Global Assessment of psoriasis; LEI: Leeds Enthesitis Index; PASI: Psoriasis Area and Severity Index.